Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 6.9x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 07 Jun 2026	US$1.3t	US$170.0b	-US$12,160,280,783.82	16.6x	-104.3x	7.5x
Tue, 05 May 2026	US$1.3t	US$167.5b	-US$11,616,741,742.25	17.2x	-108.9x	7.6x
Thu, 02 Apr 2026	US$1.3t	US$166.1b	-US$11,596,621,749.18	14.9x	-110.9x	7.7x
Sat, 28 Feb 2026	US$1.3t	US$169.4b	-US$13,319,467,287.61	21.7x	-101.1x	7.9x
Mon, 26 Jan 2026	US$1.3t	US$163.5b	-US$15,173,296,321.83	19.9x	-83.6x	7.8x
Wed, 24 Dec 2025	US$1.2t	US$163.6b	-US$15,779,683,760.87	21.6x	-78.8x	7.6x
Fri, 21 Nov 2025	US$1.2t	US$163.8b	-US$16,219,175,263.21	17.4x	-73.7x	7.3x
Sun, 19 Oct 2025	US$1.2t	US$163.4b	-US$18,206,489,780.58	16.4x	-64.1x	7.1x
Tue, 16 Sep 2025	US$1.1t	US$163.6b	-US$18,378,517,336.68	15.8x	-58.3x	6.6x
Thu, 14 Aug 2025	US$1.0t	US$163.2b	-US$14,658,010,083.94	15.6x	-70.7x	6.4x
Sat, 12 Jul 2025	US$985.4b	US$155.8b	-US$23,408,172,286.86	18.5x	-42.1x	6.3x
Mon, 09 Jun 2025	US$951.3b	US$155.9b	-US$23,930,730,032.61	16.8x	-39.8x	6.1x
Wed, 07 May 2025	US$949.3b	US$154.1b	-US$25,408,936,426.34	18.3x	-37.4x	6.2x
Fri, 04 Apr 2025	US$791.2b	US$118.6b	-US$37,117,653,368.22	21.5x	-21.3x	6.7x
Sun, 02 Mar 2025	US$850.7b	US$118.9b	-US$37,265,127,499.97	17x	-22.8x	7.2x
Tue, 28 Jan 2025	US$983.3b	US$149.5b	-US$26,320,225,889.85	17.1x	-37.4x	6.6x
Thu, 26 Dec 2024	US$990.4b	US$149.9b	-US$26,369,148,329.00	16x	-37.6x	6.6x
Sat, 23 Nov 2024	US$1.0t	US$150.0b	-US$26,559,949,256.44	17x	-37.7x	6.7x
Mon, 21 Oct 2024	US$908.0b	US$113.1b	-US$35,950,283,773.02	21.7x	-25.3x	8x
Wed, 18 Sep 2024	US$929.9b	US$113.2b	-US$35,966,527,614.94	22.9x	-25.9x	8.2x
Fri, 16 Aug 2024	US$870.9b	US$113.2b	-US$36,254,285,538.64	22.2x	-24x	7.7x
Sun, 14 Jul 2024	US$1.2t	US$164.5b	-US$28,119,714,352.84	29.4x	-42.5x	7.3x
Tue, 11 Jun 2024	US$1.2t	US$164.5b	-US$26,797,092,425.07	28.1x	-43.3x	7.1x
Thu, 09 May 2024	US$1.1t	US$164.6b	-US$26,520,766,232.38	24.3x	-42.5x	6.8x
Sat, 06 Apr 2024	US$1.1t	US$164.4b	-US$23,433,178,577.03	25x	-47.8x	6.8x
Mon, 04 Mar 2024	US$1.2t	US$167.9b	-US$21,330,880,627.75	15.9x	-56.4x	7.2x
Wed, 31 Jan 2024	US$1.4t	US$204.7b	-US$22,654,596,727.00	17.8x	-63.8x	7.1x
Fri, 29 Dec 2023	US$1.4t	US$204.9b	-US$22,192,805,164.00	19.9x	-62.8x	6.8x
Sun, 26 Nov 2023	US$1.2t	US$204.8b	-US$22,013,452,568.00	18.6x	-55.7x	6x
Tue, 24 Oct 2023	US$1.2t	US$207.5b	-US$13,040,981,709.00	16.2x	-93x	5.8x
Thu, 21 Sep 2023	US$1.3t	US$207.5b	-US$12,879,934,249.00	16.5x	-99.1x	6.1x
Sat, 19 Aug 2023	US$1.3t	US$207.6b	-US$12,299,327,844.00	17.4x	-102.8x	6.1x
Mon, 17 Jul 2023	US$1.1t	US$186.7b	-US$15,968,283,125.00	12.9x	-71.1x	6.1x
Wed, 14 Jun 2023	US$1.2t	US$186.1b	-US$15,943,311,093.00	11.8x	-73x	6.3x


US Market	-2.79%
Healthcare	0.81%
Biotech	-2.95%
Biotech	-2.95%

Company	Last Price	7D	1Y	Valuation
ABBV AbbVie	US$227.23	4.4% +US$16.8b	19.7%	PE111.7x
AMGN Amgen	US$349.58	3.8% +US$6.9b	20.4%	PE24.2x
REGN Regeneron Pharmaceuticals	US$635.45	3.4% +US$2.1b	28.8%	PE14.6x
INCY Incyte	US$102.38	5.8% +US$1.1b	48.9%	PE14.3x
LEGN Legend Biotech	US$32.62	20.1% +US$1.0b	-6.8%	PS5.3x

Announcement • Jun 04

Amgen Presents New Data Across Rare Autoimmune and Inflammatory Diseases At EULAR 2026

Amgen announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London. New data from the Phase 3 MITIGATE trial of UPLIZNA (inebilizumab) provide insights into the biology of immunoglobulin G4-related disease (IgG4-RD), while additional analyses support its long-term safety profile and sustained results in IgG4-RD. Additionally, new real-world evidence on TAVNEOS (avacopan) further support its established efficacy and safety profile with reduced steroid use in people living with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Key presentations include: Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period (OLP) of the Phase 3 MITIGATE Trial. IgG4-RD is a chronic and debilitating condition, marked by recurrent, unpredictable flares that can potentially impact multiple organs. New Phase 3 MITIGATE data further support the longer-term clinical profile of UPLIZNA. In the first year of the OLP, these data demonstrated sustained results and disease control with continued UPLIZNA treatment in patients with IgG4-RD. No patients (0%) who received UPLIZNA in the randomized controlled period (RCP) and continued with UPLIZNA in the OLP (N=56) experienced a flare, and 71.4% achieved flare-free, glucocorticoid-free complete remission at year 1 of the OLP. 5.9% of patients who received placebo in the RCP and transitioned to UPLIZNA in the OLP (N=51) experienced a flare, and 41.2% achieved flare-free, glucocorticoid-free complete remission at year 1 of the OLP. Safety results were consistent with the established safety profile of UPLIZNA. The most common adverse events in the OLP were COVID-19, upper respiratory tract infection, cough and influenza. Across the combined RCP and OLP period, median total UPLIZNA treatment exposure was 2.2 years among participants who received =1 dose of inebilizumab. The new MITIGATE data reinforce the long-term safety and efficacy profile of UPLIZNA while advancing understanding of how IgG4-RD progresses over time. Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the Phase 3 MITIGATE Trial. The first-of-its-kind natural history analysis reinforced the chronic and unpredictable nature of IgG4-RD, underscoring widespread and diverse multi-organ involvement and the need for earlier intervention and more comprehensive monitoring and risk stratification. Dynamic patterns of organ involvement over time, including the emergence of new organ manifestations and biological signals that may precede disease flares. CD19+ B cells were the first biomarker to rise ahead of a flare, followed by increases in total IgG and IgG subsets within the 30-day window preceding a flare. An additional exploratory combined analysis (Abstract #POS0089) of clinical trial RCP and OLP data in MITIGATE (N=119) showed how long-term use of UPLIZNA resulted in mostly mild immunoglobulin (Ig) reduction, with no significant association between these Ig reductions and occurrence of infections or serious infections. The incidence of infections and serious infections did not increase with each additional year of UPLIZNA treatment. The AQUARIUS analyses (Abstracts #POS01356 and #POS08673), conducted at Massachusetts General Hospital and Northwestern University, evaluated the largest U.S. real-world cohort to date of patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) treated with TAVNEOS (n=159). The findings provide new insights into clinical outcomes in patients with ANCA-associated vasculitis and are consistent with the established clinical efficacy and safety profile of TAVNEOS in patients with severe active GPA or MPA. Results highlighted variability in glucocorticoids (GCs) tapering strategies in real world practice and showed that many patients were able to taper to very low or no doses of GCs quickly. Observations underscored the complexity of managing ANCA-associated vasculitis and pointed to opportunities to further optimize treatment approaches to reduce steroid exposure while maintaining disease control. The safety profile observed in this real-world setting was consistent with the established safety profile in patients with severe active GPA or MPA. Among patients who experienced hepatic adverse events, all hepatic abnormalities were resolved. These new data reinforce that TAVNEOS can help patients achieve disease control with reduced steroid use. For more information on the full list of Amgen abstracts and presentation times, see below. All Amgen-sponsored abstracts being presented at EULAR: UPLIZNA (inebilizumab): Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period of the Phase 3 MITIGATE Trial. Immunogenicity and Impact of Anti-drug Antibodies on the Efficacy and Pharmacokinetics of Inebilizumab In MITIGATE, a Phase 3 Trial in IgG4-Related Disease. Atypical IgG4-Related Disease: Re-Examining the Entry Criteria of the2019 ACR/EULAR Classification Criteria. Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the MITIGATE Trial. Serum IgG4 Elevation in IgG4-Related Disease: A Marker of Disease Phenotype and Organ Involvement. Long-term Inebilizumab Treatment Results in Mild Immunoglobulin Reduction but No Increase in Infection Risk. TAVNEOS (avacopan): Reliability and Content Validity of a Definition of Severe Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis. Clinical Outcomes by Glucocorticoid Duration in Individuals with Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treated with Avacopan in a Real-World Setting in Two Large Healthcare Systems. One Year Real-World Effectiveness and Safety with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in Two Large Healthcare Systems. KRYSTEXXA (pegloticase): Association of Pegloticase-Induced Remission with Patient-Reported Quality of Life Outcomes in the MIRROR Randomized Controlled Trial. Reduction of Gout Flares with Pegloticase in Patients with or without Tophi at Baseline: A Post Hoc Analysis of the MIRROR Trial. Differences in Gout Management and Outcomes in Patients Referred From Primary Care to Rheumatology. Baseline Predictors of Gout Remission During Intensive Urate-Lowering with Pegloticase: Post Hoc Analysis of the MIRROR Randomized Trial.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

COO, CFO & Director recently bought US$722k worth of stock

Legend Biotech’s LB2501 Achieves 100% Response in Early B-Cell Lymphoma Trial

Praxis Precision Medicines Reassesses Vormatrigine Program After Mixed POWER1 Trial Results

BeOne Medicines Solid Tumor Pipeline Advances Boost Analyst Targets and Growth Prospects

ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution

Gilead Sciences Advances Cancer and Liver Disease Treatments With New Phase 3 Data and EMA Support

Neurocrine Biosciences Gains Momentum With Soleno Deal and CRENESSITY Data Ahead of ENDO 2026

Halozyme Therapeutics Rises 5.2% on Analyst Buy Rating and Positive Partner Trial Data

Amgen Presents New Data Across Rare Autoimmune and Inflammatory Diseases At EULAR 2026

Forecast breakeven date pushed back to 2028

Incyte Reports 25% Risk Reduction With Tafasitamab Regimen in High-Risk DLBCL Phase 3 Trial

Revolution Medicines Presents Unprecedented Results from Pivotal Phase 3 Rasolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

INSM: 2026 Respiratory Launch Execution Will Drive Bronchiectasis Leadership Debate

Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026

BNTX: Leadership Upheaval And Oncology Trial Risks Will Pressure Expectations

Regeneron’s Otarmeni Gene Therapy for Rare Hearing Loss Advances With Accelerated EMA Review